Please assess the completion status of the following clinical trial:

Trial Title: A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Have given written informed consent~* Women must not be at risk to become pregnant during study participation~* Diagnosis of Rheumatoid Arthritis (RA)~* Current, regular use of Methotrexate, at a stable dose~* Other criteria to be reviewed by study doctor~Exclusion Criteria:~* Use of excluded medications(reviewed by study doctor)~* Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy~* Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study~* Evidence of tuberculosis~* Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy~* Other criteria to be reviewed by study doctor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: EXPERIMENTAL): None
- 1 mg LY2127399 (Type: EXPERIMENTAL): None
- 3 mg LY2127399 (Type: EXPERIMENTAL): None
- 10 mg LY2127399 (Type: EXPERIMENTAL): None
- 30 mg LY2127399 (Type: EXPERIMENTAL): None
- 60 mg LY2127399 (Type: EXPERIMENTAL): None
- 120 mg LY2127399 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).